This phase II trial is evaluating the safety and response of an investigational therapy (Zanubrutinib) in patients with marginal zone lymphoma that has gotten worse or not responded to prior treatment.
This trial is treating patients with Marginal Zone Lymphoma.
This is a systemic therapy trial.
You may be able to join this trial if:
- You have had treatment but your cancer has gotten worse or has not responded to the treatment you have been given.
You may be excluded from this trial if:
- You have a certain disease or psychological condition.
- You have been diagnosed with a prior or secondary type of cancer.
- You have previously been treated (or are currently being treated) on a clinical trial.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
Clinical Summary Read More
Use the hyperlinks, where available to access additional clinical trial information.
A Phase 2, Open-label Study of Zanubrutinib (BGB-3111) in Patients With Relapsed or Refractory Marginal Zone Lymphoma
BeiGene Australia Pty Ltd
In this trial, patients will be assigned to a single arm to receive Zanubrutinib at a dose of 160 mg PO BID.
Recruiting Hospitals Read More